Home/Pipeline/SRSD101

SRSD101

Not Disclosed

Phase 1Active

Key Facts

Indication

Not Disclosed

Phase

Phase 1

Status

Active

Company

Sirius Therapeutics

About Sirius Therapeutics

Sirius Therapeutics is an innovative, privately-held biotech advancing a pipeline of siRNA therapies targeting major chronic diseases, with lead programs in Phase 2 and Phase 1/2a trials. The company has established a strong operational footprint in both the US and China, securing funding from top-tier investors like OrbiMed and forging a strategic collaboration with CRISPR Therapeutics. Its strategy is built on three 'mega-blockbuster' franchises in cardiovascular and metabolic diseases, supported by its proprietary PEPR siRNA technology platform.

View full company profile

Therapeutic Areas

Cardiovascular Metabolic Disease Coagulation Disorders Obesity

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active